6 223

Cited 10 times in

Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma

 Hye Sun Shin  ;  Seung Up Kim  ;  Jun Yong Park  ;  Do Young Kim  ;  Kwang-Hyub Han  ;  Chae Yoon Chon  ;  OidovBaatarkhuu  ;  Sang Hoon Ahn 
 Journal of Gastroenterology and Hepatology, Vol.27(9) : 1528-1534, 2012 
Journal Title
 Journal of Gastroenterology and Hepatology 
Issue Date
Adult ; Aged ; Antiviral Agents ; Carcinoma, Hepatocellular/blood ; Carcinoma, Hepatocellular/pathology* ; Carcinoma, Hepatocellular/virology ; Chi-Square Distribution ; DNA, Viral/blood ; Drug Resistance, Viral/genetics ; Female ; Genotype ; Guanine/analogs & derivatives* ; Guanine/therapeutic use ; Hepatitis B e Antigens/blood ; Hepatitis B virus/genetics ; Hepatitis B virus/immunology ; Hepatitis B, Chronic/complications ; Hepatitis B, Chronic/drug therapy* ; Humans ; Kaplan-Meier Estimate ; Lamivudine/therapeutic use* ; Liver Neoplasms/blood ; Liver Neoplasms/pathology* ; Liver Neoplasms/virology ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Retrospective Studies ; Severity of Illness Index ; alpha-Fetoproteins/metabolism
efficacy ; entecavir ; hepatitis B virus hepatocellular carcinoma ; lamivudine
BACKGROUND AND AIM: Little information is available about the antiviral efficacy of lamivudine (LAM) and entecavir (ETV) in patients with hepatitis B virus (HBV)-related advanced hepatocellular carcinoma (HCC). Thus, we compared the antiviral efficacy of LAM and ETV in these patients. METHODS: The medical records of 134 antiviral therapy-naïve patients with HBV-related advanced HCC (modified Union for International Cancer Control [UICC] Tumor, Nodes, and Metastases [TNM] stages III-IV) treated between January 2005 and September 2009 were reviewed. After HCC diagnosis, 87 (64.9%) and 47 (35.1%) patients received LAM and ETV, respectively. RESULTS: The mean age of patients (115 men, 19 women) was 53 years. Sixty-five (48.5%) and 69 (51.5%) patients had TNM stages III and IV HCC, respectively. Treatment outcomes during follow-up, including virologic, biochemical, and serologic responses and appearance of antiviral resistance, were similar in the LAM and ETV groups (all P>0.05). Multivariate analysis identified Child-Pugh class, α-fetoprotein, and TNM stage as independent predictors of overall survival (all P<0.05). Antiviral agent type (LAM vs ETV) did not influence overall survival (median 9.6 months in LAM vs 13.6 months in ETV group; P=0.493). HCC treatment was not interrupted due to HBV flare up in any patient. CONCLUSIONS: The antiviral efficacy of LAM and ETV was similar and the type of antiviral agent did not influence overall survival in patients with HBV-related advanced HCC. Thus, LAM, which is less expensive than ETV in Korea, might be sufficient to control HBV in these patients.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영)
Kim, Seung Up(김승업) ORCID logo https://orcid.org/0000-0002-9658-8050
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Shin, Hye Sun(신혜선)
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Chon, Chae Yoon(전재윤)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.